NAMSNewAmsterdam Pharma Company N.V.
Price
-19%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality mixed, a flag to check, growth fading, the market against it.
We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $3.7M in Q2 2026 (quarter ended Jun 30, 2026), down 81% from the same quarter a year earlier. That came with net loss of $64M. For the full year FY2025, revenue was $23M (−51% year on year) and net income −$204M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 29, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease.Other event · Form 8-K
- Sep 21, 2026On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Evlarco ® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose …Other event · Form 8-K
- Aug 14, 2026As previously disclosed on July 22, 2026, Douglas Kling resigned as the Company’s Chief Operating Officer, effective August 14, 2026 (the “Separation Date”), to be appointed as the chief executive officer of another clinical-stage biotech company.Director or officer change · Form 8-K/A
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.